Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2020 06:30 ET | Source: Emergent BioSolutions

EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage...
March 11, 2020 16:21 ET | Source: Emergent BioSolutions

Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease

Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) being developed as a potential treatment for severe hospitalized patients and protection for at-risk individualsEquine-derived...
March 10, 2020 05:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent...
February 20, 2020 16:31 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019

GAITHERSBURG, Md., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS (in...
February 03, 2020 16:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020

GAITHERSBURG, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the...
January 31, 2020 09:26 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency

GAITHERSBURG, Md., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
January 13, 2020 06:40 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate

GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed...
January 13, 2020 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast

Full year 2019 preliminary revenues and adjusted profitability metrics in line with prior guidanceFull year 2020 forecast reflects continued growth of core business as well as investments in key...
January 06, 2020 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
December 20, 2019 13:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors

GAITHERSBURG, Md., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have...